Lipids & metabolic liver disease
Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated and GRADE Assessed Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Authors' conclusion
Oral PCSK9 inhibitors were associated with clinically meaningful improvements in multiple lipid parameters while maintaining a favourable short-term safety profile.
Study context
- Population
- Adults with hypercholesterolemia; RCTs searched in PubMed, Embase and Scopus from inception to March 2026
- Participants
- 4,268 adults5 RCTs
- Comparison
- Oral PCSK9 inhibitors vs placebo
- Outcome
- Changes in low-density lipoprotein cholesterol (LDL-C) and triglycerides
Methodological detailsPRISMA, random-effects models, RoB2 risk of bias, GRADE certainty assessment
- PRISMA
- Random-effects models
- RoB2 risk of bias
- GRADE certainty assessment
Pooled result
As reported in the abstract
Each group vs placeboEstimate (95% CI)P value
Oral PCSK9 inhibitors
MD (LDL-C) −49.49 mg/dL(−54.81 to −44.18)
P < 0.00001Oral PCSK9 inhibitors
MD (triglycerides) −11.65 mg/dL(−15.53 to −7.78)
P < 0.00001Further pooled results
Other lipid parameters
- Significant reductions in non-HDL cholesterol, apolipoprotein B, lipoprotein(a) and total cholesterol
- Dose-dependent effects, with greater reductions at higher doses
Mortality
- No significant difference in mortality
Safety
- No significant difference in overall adverse events
- Treatment discontinuation due to adverse events was lower with intervention
Original publication
Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated and GRADE Assessed Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Diabetes Obes Metab. Published 10 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →